We are now offering a new and innovative treatment with SPRAVATO® (esketamine).

This is a very promising treatment for people who have suffered from moderate to severe depression for many years with previous ineffective trials of traditional psychotropic medications. SPRAVATO® (esketamine) is working very differently compared to traditional antidepressant medications

__________________________________________________________________

 As an NMDA (N-methyl D-aspartate) glutamate receptor antagonist it increases glutamate levels in the brain, which alleviates the symptoms of depression, enhances memory and the brain’s learning function.

Research shows that under chronic stress, the connection between neurons (brain cells) diminishes. Esketamine works on restoring those connections via growth-promoting effect as well as preventing the neurotoxic effects of depression.

​

Please visit www.spravato.com for more information. ​

If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression(TRD).

Medical Indications:

​

SPRAVATO® is a prescription medicine, used along with an antidepressant, taken by mouth to treat:

• Adults with treatment-resistant depression (TRD)

• Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® can cause serious side effects, including:

​

• Sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).

  • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.

  • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.

• Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®.

  • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

  • Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.

• SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

• Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed.

SPRAVATO® is not for use in children

​​​